Strattera binge eating disorder

Atomoxetine (Strattera) is a selective norepinephrine reuptake inhibitor (SNRI) used to treat attention-deficit hyperactivity disorder (ADHD), narcolepsy, and schizophrenia. Atomoxetine belongs to the class of drugs known as non-benzodiazepine hypnotics, and its use has been associated with an increase in the risk of suicidal thinking and behavior.

Strattera is approved by the FDA for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD), narcolepsy, and schizophrenia in adults and adolescents ages 13-17 years. The drug is indicated for the treatment of these conditions through both inpatient and outpatient treatment plans. Strattera also has a sedating effect when administered orally, which may decrease the risk of overdose. Patients should be aware that the use of Strattera is not recommended for the treatment of ADHD.

Mechanism of Action

Atomoxetine belongs to the category of drugs known as non-benzodiazepine hypnotics, and its sedating effect is believed to decrease the risk of suicidality and agitation associated with alcohol intoxication. Atomoxetine also causes the inhibition of norepinephrine reuptake in the brain, which helps to decrease impulsivity, hyperactivity, and irritability, and may be useful for the treatment of ADHD. It has a similar mechanism of action as the benzodiazepine, with a greater affinity for the 5-HT2A receptors, and the norepinephrine transporter. In addition, atomoxetine may cause sedation, hypotension, coma, and other effects.

Indications

Atomoxetine is indicated for the treatment of attention-deficit hyperactivity disorder (ADHD), narcolepsy, and schizophrenia in adults and adolescents ages 13-17 years. It is indicated for the treatment of these conditions through both inpatient and outpatient treatment plans. Strattera may also be indicated in combination with other medications for the management of hyperactivity and impulsivity, as well as for the treatment of schizophrenia and bipolar disorder.

Dosage & Administration

Atomoxetine should be taken orally as directed by a doctor, and the dosage may vary depending on the patient's response to the drug and their tolerance and tolerability. The usual starting dose is 40 mg once daily, taken once or twice a day. The maximum recommended dosing frequency is once per day. Patients should be aware that the use of atomoxetine is not recommended for the treatment of ADHD. It can also have sedating effects, and the drug may decrease the risk of suicidality and agitation associated with alcohol intoxication. The drug should be taken orally with a full glass of water, with at least a full glass of milk. To reduce the risk of overdose, patients should be aware that the use of atomoxetine is not recommended for the treatment of ADHD.

Contraindications

Atomoxetine should not be used in the following cases:

  • Patients with severe liver impairment
  • Patients with severe renal impairment
  • Patients with hypersensitivity to the active substance or to any of its components
  • Patients with a history of allergic reactions to atomoxetine or any of its components
  • Patients with hypersensitivity to any of its components or any other excipients

Dosage & Administration Schedule

The dosage of Atomoxetine is based on the patient's response and tolerance to the drug. Atomoxetine is available in oral suspension, tablet, and capsule form. The typical starting dose is 40 mg once daily, taken once or twice a day.

Introduction to Strattera

Strattera, commonly known as atomoxetine, is a non-stimulant medication used to treat Attention Deficit Hyperactivity Disorder (ADHD). It contains the active ingredient Strattera, which works by affecting the levels of nerve-derived substances in the brain, particularly norepinephrine and dopamine. This ability to improve impulse control has been a mainstay in the treatment of ADHD. Unlike other types of medications that increase the levels of dopamine and norepinephrine, Strattera does not directly cause these chemicals to be low in levels. Instead, it targets the norepinephrine transporter, thus increasing the levels of dopamine and norepinephrine in the brain.

Market Size and Growth

The global ADHD market is expected to experience significant growth over the coming years. As of 2023, the market size was valued at USD 2.59 billion. It is projected to grow at a Compound Annual Growth Rate (CAGR) of 5.45% from 2024 to 2030, reaching aCAGR of 6.5% during the same period based on report fromVerified Medical Market Research (VFMMR).

In the pharmacoepidemiology analysis (Pha) space, the growth rate was 6.6% from 2024 to 2030, indicating a CAGR of 6.5% during that period[3]. Market growth segments and revenue drivers include;

  • Adults and SeniorsThe market is expected to experience steady growth driven by aging populations and the rising prevalence of ADHD. As the aging population ages, it becomes more difficult for individuals to follow simple instructions and carry out routine tasks, leading to increased difficulty in managing behavior and impulse control[5].
  • ADHD Drugs and FoodsAdults and Seniors are becoming more reliant on the over-the-counter drugs and foods they consume, contributing to a drop in ADHD medication use in the forecast period. The availability of these drugs and foods has led to a surge in ADHD medication use, with usage reaching double-digit increases over the forecast period[1][4].

Key Players

  • Tacrolimus (Nacbinox) e.g. Eliquis, Risperdal
  • Dexmethylphentermine (Tambocor) e.g. Rolaids, Adderall
  • Phentermine (Bupivacaine) e.g. Qsyst, Adderall
  • Phenothiazines like methylphenidate (QZIP) e.g. Upjohn, Allergan
  • Methylphenidate (QRXQ) e.g. Rolaids, Risperdal
  • Risperidone (Risperdal) e.g. Zyprexa, Risperdal Zydus, Risperdal Ketamine
  • Other

Market Segment Analysis

  • Market Size: The global ADHD drug and food market was valued at USD 2.59 billion in 2023 and is expected to grow at a CAGR of 6.5% from 2024 to 2030[3].
  • Historical Market Size: The market size was valued at USD 2.3 billion in 2023 and is expected to reach a size of USD 4.18 billion by 2030[3].
  • Xcelspanescriptive Recent Market Size and Forecast: The 2023 global ADHD drug and food market was valued at USD 2.5 billion and USD 3.1 billion, with a projected 2023 CAGR of 2034. The 2034 market size was anticipated to grow at a Compound Annual Growth Rate (CAGR) of 5.46% from 2024 to 2030[3].

Salt Composition in both

Salt Composition

Atomoxetine 30mg(same for both)

You Searched

Strattera 30mg Tablet

Novartis India Ltd.

Strip of 10 tablets

We only sell the best substitute from top brands

Our Recommendation

Atomaforce 30mg Tablet 10s

Cipla Ltd.

2,554+ Customers trust this

WHO GMP Certified

Marketed by

Doctor ApprovedMedicine Comparison

Disclaimer

PlatinumRx is dedicated to delivering dependable and trustworthy information to empower our customers. However, the information presented here is solely for general informational purposes and should not be utilized for diagnosing, preventing, or treating health issues. It is not intended to establish a doctor-patient relationship or serve as a substitute for professional medical advice.

Top Selling Medicines

Pantosec DSR 30/40mg PR Capsule 10sPantosec 40mg Tablet 10sCipvildin M 500/50mg Tablet 15sAb Rozu 10mg Tablet 10sCipcal D3 60000IU Capsule 4sCipcal 500mg/250IU Tablet 15sDapaquest 10mg Tablet 10sMontecip LC 5/10mg Tablet 10sLipvas 10mg Tablet 10sParacip 650mg Tablet 10sView More

Top Selling Devices

Aerolife inhalation Device 1sAir Space Wit Exhle Valve Device 1sBp Monitor (Omron) Hem 8712 Device 1sContour Plus System 1sDigital Thermometer Mercury Device 1sDuohaler DPI Device 1sIbreathe DPI Inhealer Device 1sMachaler DPI Device 1sMacspacer Device 1sNovopen 4 | Diabetes Monitoring Devices 1s

New Productaginousards. This product will not work properly.aginadox 50 mg tablet 25 mg oral solution 20 ml/100 ml tablet 20 ml/100 s forceps. dapoxetine 60mg/g tablet 20 ml/100 g powder for injection. dapoxetine 60mg/g in syrup. dapoxetine 60mg/g oral suspension. dapoxetine 60mg/g suspension. dapoxetine 60mg/g in powder for injection. dapoxetine 60mg in powder for injection. Bacitracin Sinus Infection. Dapoxetine 60mg/g in syrup.

Atomoxetine and Strattera are prescription medications used to treat Attention Deficit Hyperactivity Disorder (ADHD) and other behavioral disorders.

The medications are a class of drugs that work by increasing the levels of a neurotransmitter called norepinephrine in the brain.

Strattera, on the other hand, belongs to a class of medications called atypical antipsychotics. These medications are used to treat symptoms of ADHD.

These medications are also prescribed for the treatment of narcolepsy, which is a sleep disorder.

When a person has ADHD, the brain’s reward system sends chemical messages to areas of the body that control attention, focus, and impulsivity.

ADHD affects approximately one in eight people who take medications for the disorder.

ADHD is characterized by the inability to stay focused on tasks for at least two to four hours.

Atomoxetine, the active ingredient in Strattera, is a prescription drug.

It’s not known if Strattera is addictive or not.

How Strattera and Atomoxetine Affect the Brain

Both Strattera and Atomoxetine affect the brain’s reward system.

Strattera, in particular, affects the amount of norepinephrine that the brain receives from the nerves. Norepinephrine is a chemical that signals the brain to send signals to the rest of the body to help control behavior and other brain functions.

Atomoxetine, on the other hand, also affects the levels of norepinephrine in the brain. Low levels of norepinephrine in the brain cause symptoms of ADHD, such as difficulty staying awake, feeling tired, and experiencing poor concentration.

The effects of Strattera and Atomoxetine on the brain may last up to two to three hours.

Strattera and Atomoxetine’s Impact on the Body

Strattera, the generic version of atomoxetine, has the same active ingredient as Atomoxetine. Atomoxetine, the brand name for the medication, is a selective norepinephrine reuptake inhibitor (norepinephrine reuptake inhibitor) and a central nervous system (CNS) stimulant. Strattera increases the amount of norepinephrine in the brain.

Atomoxetine, however, affects the levels of norepinephrine in the brain. This means that Strattera, while not addictive, can cause side effects such as trouble sleeping, nausea, and sweating.

Atomoxetine, on the other hand, may cause side effects such as irritability, nausea, sweating, and dizziness. It’s important to note that these side effects are uncommon and often mild.

In some cases, Strattera and Atomoxetine may cause a serious condition called.

A doctor may need to perform blood tests to make sure that Strattera and Atomoxetine are not causing any serious side effects.

It’s also important to tell a doctor about all the medications you take, as well as any allergies or other illnesses.

Taking Strattera and Atomoxetine with certain medications can sometimes lead to serious side effects or other drug interactions. If you have a history of allergies or other problems with your blood pressure, you may be more at risk for Strattera and Atomoxetine interactions.

It’s also important to tell your doctor about all the medications you take, as well as all the products you buy at eDrugstore.com.

Drug interactions can sometimes lead to dangerous side effects. If you experience any of these symptoms, call your doctor immediately.

Strattera and Atomoxetine’s Side Effects

Like all prescription medications, Strattera and Atomoxetine can cause side effects.

Strattera (Atomoxetine)

Play pronunciationStrattera

Contains Atomoxetine as the active ingredient.

Available as a generic alternative.

Indications

Strattera is used for the treatment of attention deficit hyperactivity disorder (ADHD). It may also be used for the treatment of:

  • Schizophrenia
  • Bipolar I disorder
  • Major depressive disorder
  • Obsessive-compulsive disorder (OCD)
  • Post-traumatic stress disorder

Note:The drug is also approved for the treatment of depression.

Dosage

Adults and children over 12 years:The dosage of atomoxetine is determined by your doctor.

Children under 12 years:Strattera can be used for the treatment of depression in children aged 12 years and older.

Uses

The dosage of atomoxetine depends on the indication and age. Atomoxetine is prescribed for the treatment of ADHD in adults and children under 12 years of age.

Precautions

The dose and duration of atomoxetine should be determined by your doctor. Atomoxetine is not recommended for children under 12 years of age.

Interactions

Strattera may interact with other medications. It is important to inform your doctor about all the medicines you take, including prescription and non-prescription drugs, vitamins, and herbal products. Your doctor will decide which medicines should not be taken.

Possible side effects

Side effects may include:

  • drowsiness
  • nausea
  • constipation
  • dizziness
  • diarrhea
  • dry mouth
  • fast, shallow breathing
  • headache
  • flushing
  • sweating
  • skin rash
  • sleepiness
  • trouble falling asleep
  • weakness

Stop taking atomoxetine and seek medical attention if any of these symptoms occur.

Strattera should not be taken with certain medicines. Some medicines can affect how atomoxetine works.